BMS, Pfizer’s fast-growing Eliquis is about to steamroll market-leader warfarin: exec

Last year, Pfizer and Bristol-Myers Squibb’s Eliquis replaced Johnson & Johnson’s Xarelto as the leader of the novel oral anticoagulant class. And now, thanks to a $1.65 billion performance in the second quarter, it’s about to unseat an even bigger foe: warfarin, the drug that’s been a standard therapy for decades.